Target intelligence / Profile preview

Peripheral myelin protein 2 (PMP2)

Target
PMP2
Molecular classification
Fatty acid-binding protein, Calycin superfamily, Myelin structural protein
01

Overview

Peripheral myelin protein 2 (PMP2) is a small β-barrel fatty acid-binding protein localized predominantly to the myelin sheaths of the peripheral nervous system[1][2][3]. It binds monomeric lipids (fatty acids, cholesterol) inside its cavity, and its hydrophobic, positively charged exterior interacts directly with membranes and promotes their stacking, contributing crucially to the formation and maintenance of compact myelin structure needed for proper nerve insulation and conduction[1][2][3]. Mutations in the PMP2 gene have been causally linked to dominant forms of demyelinating Charcot–Marie–Tooth peripheral neuropathy, typically resulting in destabilized protein, impaired lipid binding, and abnormal myelin ultrastructure manifesting as reduced nerve conduction and clinical neuropathy symptoms[1][2][3]. Recent research further shows PMP2 can influence sphingomyelin organization at the plasma membrane in a PI(4,5)P2-dependent manner and may be regulated by SOX10, implicating it in melanoma cell invasion[1]. Thus, PMP2 is an essential lipid-binding and structural protein of peripheral myelin, with established roles both in neurological disease and possibly cancer biology.

Other names
Myelin P2 proteinPMP2MP2FABP8M-FABPP2CMT1G
02

Biological functions

Lipid transportMembrane stackingMyelin sheath assemblyMaintenance of myelin stabilityModulation of membrane lipid dynamicsRegulation by SOX10 (in cancer)
03

Disease associations

Neurodegenerative disease (notably Charcot-Marie-Tooth disease)Oncogenesis (melanoma cell invasion)
04

Safety considerations

Mutations may lead to destabilized protein and impaired fatty acid binding, contributing to peripheral neuropathiesTherapeutic targeting of myelin proteins carries risk of demyelination or exacerbation of neurological symptoms
05

Biomarkers

Gene mutations (e.g., p.I43N, p.Thr51Pro, p.Ile52Thr, I50del, M114T, V115A) as biomarkers for dominant demyelinating Charcot-Marie-Tooth neuropathy

Beyond the preview

Go deeper on Peripheral myelin protein 2 (PMP2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peripheral myelin protein 2 (PMP2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call